422.63
price down icon0.89%   -3.81
after-market After Hours: 422.63
loading
Vertex Pharmaceuticals Inc stock is traded at $422.63, with a volume of 1.76M. It is down -0.89% in the last 24 hours and up +11.30% over the past month. Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$426.44
Open:
$427.85
24h Volume:
1.76M
Relative Volume:
0.97
Market Cap:
$108.36B
Revenue:
$11.39B
Net Income/Loss:
$3.64B
P/E Ratio:
30.21
EPS:
13.9904
Net Cash Flow:
$3.50B
1W Performance:
+3.43%
1M Performance:
+11.30%
6M Performance:
-14.17%
1Y Performance:
-10.09%
1-Day Range:
Value
$421.26
$432.76
1-Week Range:
Value
$406.76
$432.76
52-Week Range:
Value
$362.50
$519.88

Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile

Name
Name
Vertex Pharmaceuticals Inc
Name
Phone
(617) 341-6393
Name
Address
50 NORTHERN AVENUE, BOSTON, MA
Name
Employee
6,100
Name
Twitter
@VertexPharma
Name
Next Earnings Date
2025-02-10
Name
Latest SEC Filings
Name
VRTX's Discussions on Twitter

Compare VRTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
422.63 109.29B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
464.00 62.13B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
575.69 61.40B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.18 51.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
310.03 34.68B 4.56B -176.77M 225.30M -1.7177

Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-25-25 Upgrade Leerink Partners Market Perform → Outperform
Sep-03-25 Initiated Raymond James Mkt Perform
Aug-06-25 Upgrade Wells Fargo Equal Weight → Overweight
May-07-25 Downgrade Wolfe Research Outperform → Peer Perform
May-06-25 Downgrade Leerink Partners Outperform → Market Perform
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Feb-12-25 Upgrade Canaccord Genuity Sell → Hold
Feb-11-25 Upgrade Canaccord Genuity Sell → Hold
Jan-30-25 Downgrade Wells Fargo Overweight → Equal Weight
Dec-20-24 Reiterated H.C. Wainwright Buy
Dec-19-24 Downgrade Oppenheimer Outperform → Perform
Dec-09-24 Upgrade Jefferies Hold → Buy
Nov-14-24 Initiated Citigroup Buy
Oct-16-24 Initiated Scotiabank Sector Perform
Oct-10-24 Resumed Raymond James Mkt Perform
Aug-05-24 Downgrade Barclays Overweight → Equal Weight
Jun-27-24 Initiated Redburn Atlantic Buy
Apr-11-24 Upgrade Evercore ISI In-line → Outperform
Feb-15-24 Initiated Wolfe Research Outperform
Feb-06-24 Downgrade Evercore ISI Outperform → In-line
Feb-02-24 Downgrade Bernstein Outperform → Mkt Perform
Jan-31-24 Downgrade Maxim Group Buy → Hold
Jan-31-24 Downgrade Robert W. Baird Neutral → Underperform
Jan-24-24 Downgrade Canaccord Genuity Hold → Sell
Dec-14-23 Reiterated RBC Capital Mkts Sector Perform
May-30-23 Initiated William Blair Outperform
May-04-23 Resumed Piper Sandler Overweight
Mar-21-23 Initiated Bernstein Outperform
Jan-18-23 Initiated Canaccord Genuity Hold
Jan-17-23 Upgrade SVB Leerink Mkt Perform → Outperform
Dec-19-22 Downgrade Jefferies Buy → Hold
Jul-13-22 Initiated Cantor Fitzgerald Overweight
Jun-01-22 Upgrade Maxim Group Hold → Buy
May-23-22 Initiated SVB Leerink Mkt Perform
May-06-22 Downgrade Robert W. Baird Outperform → Neutral
May-03-22 Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-03-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jan-27-22 Reiterated JP Morgan Overweight
Jan-27-22 Reiterated Morgan Stanley Underweight
Jan-27-22 Reiterated RBC Capital Mkts Outperform
Jan-27-22 Reiterated Stifel Hold
Jan-27-22 Reiterated Wolfe Research Outperform
Jan-20-22 Upgrade BMO Capital Markets Market Perform → Outperform
Dec-09-21 Initiated Wells Fargo Overweight
Nov-19-21 Initiated BMO Capital Markets Market Perform
Nov-19-21 Downgrade Piper Sandler Overweight → Neutral
Sep-09-21 Downgrade Stifel Buy → Hold
Sep-07-21 Downgrade Morgan Stanley Equal-Weight → Underweight
Jul-20-21 Downgrade SVB Leerink Mkt Perform → Underperform
Jul-19-21 Resumed Wolfe Research Outperform
Jul-01-21 Initiated Raymond James Mkt Perform
Jun-11-21 Downgrade Daiwa Securities Outperform → Neutral
Feb-23-21 Upgrade Robert W. Baird Neutral → Outperform
Feb-02-21 Reiterated H.C. Wainwright Buy
Dec-30-20 Initiated Daiwa Securities Outperform
Nov-30-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-20-20 Initiated Bernstein Outperform
Oct-28-20 Initiated UBS Buy
Jul-31-20 Reiterated H.C. Wainwright Buy
Jul-08-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-30-20 Reiterated H.C. Wainwright Buy
Apr-28-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-04-20 Initiated Barclays Overweight
Jan-31-20 Downgrade Robert W. Baird Outperform → Neutral
Nov-19-19 Upgrade Guggenheim Neutral → Buy
Nov-12-19 Initiated SunTrust Buy
Oct-17-19 Resumed BofA/Merrill Buy
Sep-03-19 Upgrade Goldman Neutral → Buy
Aug-01-19 Downgrade Needham Buy → Hold
May-23-19 Resumed Citigroup Buy
May-21-19 Initiated Credit Suisse Outperform
Apr-12-19 Initiated Evercore ISI In-line
Mar-26-19 Upgrade William Blair Mkt Perform → Outperform
Mar-19-19 Downgrade SVB Leerink Outperform → Mkt Perform
Feb-06-19 Downgrade Maxim Group Buy → Hold
View All

Vertex Pharmaceuticals Inc Stock (VRTX) Latest News

pulisher
09:13 AM

Advocacy groups form a buyer's club to obtain generic versions of pricey Vertex cystic fibrosis drug - statnews.com

09:13 AM
pulisher
02:16 AM

Did FDA Progress on Povetacicept and New Data for ALYFTREK Just Shift Vertex’s (VRTX) Investment Narrative? - Yahoo Finance

02:16 AM
pulisher
09:03 AM

Vertex (NASDAQ: VRTX) NACFC: - Stock Titan

09:03 AM
pulisher
08:59 AM

Long term hold vs stop loss in Vertex Pharmaceuticals Incorporated2025 Price Action Summary & Weekly Stock Performance Updates - newser.com

08:59 AM
pulisher
08:12 AM

Vertex price extends gainsForecast today23-10-2025 - Economies.com

08:12 AM
pulisher
07:30 AM

How Vertex Pharmaceuticals Incorporated (VX1) stock compares with top peers2025 Top Gainers & Free Technical Pattern Based Buy Signals - newser.com

07:30 AM
pulisher
06:28 AM

Real time pattern detection on Vertex Pharmaceuticals Incorporated stockTrade Ideas & Real-Time Chart Breakout Alerts - newser.com

06:28 AM
pulisher
05:46 AM

Will Vertex Pharmaceuticals Incorporated bounce back from current supportPortfolio Update Summary & High Conviction Buy Zone Alerts - newser.com

05:46 AM
pulisher
05:44 AM

Is Vertex Pharmaceuticals Incorporated stock supported by innovation pipeline2025 Bull vs Bear & Stock Portfolio Risk Control - newser.com

05:44 AM
pulisher
04:27 AM

Promising Biotech Stocks To ResearchOctober 19th - MarketBeat

04:27 AM
pulisher
04:09 AM

Using data tools to time your Vertex Pharmaceuticals Incorporated exitJuly 2025 Outlook & Precise Trade Entry Recommendations - newser.com

04:09 AM
pulisher
02:10 AM

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com

02:10 AM
pulisher
Oct 22, 2025

Bank of America Securities Remains Bullish on Vertex Pharmaceuticals Incorporated (VRTX) - Insider Monkey

Oct 22, 2025
pulisher
Oct 22, 2025

Vertex Pharmaceuticals (NDQ:VRTX): Another >US$100bn biotech that is facing the cliff like its peers, but might be safer - Stocks Down Under

Oct 22, 2025
pulisher
Oct 22, 2025

Custom watchlist performance reports with Vertex Pharmaceuticals Incorporated2025 Fundamental Recap & AI Driven Stock Price Forecasts - newser.com

Oct 22, 2025
pulisher
Oct 21, 2025

Published on: 2025-10-21 19:18:02 - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain marketsTrade Exit Summary & Safe Entry Zone Identification - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Why Vertex Pharmaceuticals Incorporated (VX1) stock remains top ratedWeekly Trade Recap & Daily Profit Maximizing Tips - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 21, 2025
pulisher
Oct 21, 2025

Published on: 2025-10-21 14:48:46 - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

VRTX Stock Quote Price and Forecast - CNN

Oct 21, 2025
pulisher
Oct 21, 2025

Vertex wins approval of new cystic fibrosis therapy Alyftrek - MSN

Oct 21, 2025
pulisher
Oct 21, 2025

Published on: 2025-10-21 05:18:25 - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Momentum divergence signals in Vertex Pharmaceuticals Incorporated chart2025 Analyst Calls & Weekly Top Gainers Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

How big funds are accumulating Vertex Pharmaceuticals Incorporated (VX1) stock2025 AllTime Highs & Safe Capital Growth Trade Ideas - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

How Vertex Pharmaceuticals Incorporated (VX1) stock valuation compares with sector2025 Support & Resistance & Technical Pattern Recognition Alerts - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

Is Vertex Pharmaceuticals Incorporated (VX1) stock considered safe havenRisk Management & Low Drawdown Momentum Ideas - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

Vertex Pharmaceuticals (VRTX) Investor Outlook: Analyzing A 15% Upside Potential - DirectorsTalk Interviews

Oct 20, 2025
pulisher
Oct 20, 2025

Promising Biotech Stocks To Follow TodayOctober 18th - MarketBeat

Oct 20, 2025
pulisher
Oct 19, 2025

Earnings Preview: What To Expect From Vertex Pharmaceuticals' Report - MSN

Oct 19, 2025
pulisher
Oct 18, 2025

Will Vertex Pharmaceuticals Incorporated stock beat EPS estimates2025 Big Picture & Daily Entry Point Trade Alerts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

A Closer Look at Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Stability - Yahoo Finance

Oct 18, 2025
pulisher
Oct 17, 2025

Guidance Update: Is Vertex Pharmaceuticals Incorporated stock a buy for dividend growth2025 Trading Volume Trends & AI Driven Price Predictions - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - sharewise.com

Oct 17, 2025
pulisher
Oct 17, 2025

Is Vertex Pharmaceuticals Incorporated stock a buy for dividend growthBond Market & High Conviction Buy Zone Alerts - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Vertex IgA nephropathy asset povetacicept granted FDA rolling review - MSN

Oct 17, 2025
pulisher
Oct 17, 2025

Vertex Pharmaceuticals (VRTX) Advances Povetacicept for Kidney D - GuruFocus

Oct 17, 2025
pulisher
Oct 17, 2025

Goldman Sachs Cuts Vertex Pharmaceuticals Price Target to $603 From $624, Buy Rating Kept - MarketScreener

Oct 17, 2025

Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$464.00
price down icon 0.19%
$575.69
price down icon 1.55%
$812.18
price down icon 0.24%
biotechnology ONC
$310.03
price down icon 1.12%
$160.12
price down icon 0.17%
Cap:     |  Volume (24h):